Rosuvastatin (Crestor), a new, highly efficacious statin, has demonstrated dose-dependent low-density lipoprotein cholesterol (LDL-C) reductions of up to 65% in a dose-ranging programme with doses of 1 to 80 mg. A randomized, double-blind multicentre trial compare...
Jones PH,Cusi K,Davidson MH,et al.Efficacy and safety of fenofibric acid co-administered with low-or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus:results of a pooled subgroup analysis from three randomized,controlled,double-blind trials. American Journal ...
Statin therapy decreases low-density lipoprotein cholesterol levels and the risk of coronary heart disease but has a considerable short-term effect on health care budgets. The cost effectiveness of rosuvastatin (Crestor) has been compared with those of atorvastatin, pravastatin, and simvastatin in ...